Repare Therapeutics has dosed the first subject in its Phase I POLAR clinical trial of RP-3467, a Polθ ATPase inhibitor, as a potential treatment for various solid tumours.
The POLAR trial is the fourth clinical programme of Repare.
Go deeper with GlobalData
The open-label, multicentre, dose-escalation Phase I trial aims to assess the safety, pharmacokinetics, pharmacodynamics and initial clinical activity of RP-3467.
RP-3467 will be administered alone or along with the PARP inhibitor olaparib to adults with molecularly selected advanced solid tumours.
Individuals with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer or pancreatic adenocarcinoma are eligible, and 52 will be enrolled in the study.
The trial’s primary objective is to assess the safety and tolerability of RP-3467, both as a monotherapy and in combination with Olaparib.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe trial will also define a preliminary recommended Phase II dose of RP-3467 when used with olaparib.
Repare Therapeutics executive vice-president and chief medical officer Maria Koehler stated: “RP-3467, our potential best-in-class Polθ ATPase inhibitor, has demonstrated highly compelling preclinical results, including complete and durable tumour regressions in combination with olaparib, the leading PARP inhibitor, with no additive toxicities. This combination is designed to meaningfully improve patient outcomes by mitigating PARP inhibitor resistance, a significant area of high unmet medical need.
“In addition, Repare’s previously reported data established the potential for RP-3467 to improve efficacy and limit toxicity in combination with radioligand therapy and chemotherapy-bearing antibody-drug conjugates (ADCs), and we look forward to exploring those areas.”
In August 2024 the company announced plans to reduce its workforce by around 25% as it prioritises operations on its four clinical programmes in oncology indications and shuns new candidate discoveries.
